An online book that explains mortality and cancer risks of sleeping pills, and which of today's Most of the patients in this study were taking zolpidem or temazepam As expected, these chronic insomniacs slept about 20-27 min. more for the first two days The recommended dosage is much lower than the 1-5 mg.
We do not have clear evidence that one sleeping pill has more cancer risk than another. For patients prescribed over 132 sleeping pills per year, there was a 35% increased risk of developing cancer within an average of 2.5 years. In our epidemiologic study, we only demonstrated statistically significant cancer risks for zolpidem and temazepam, the most popular drugs in that study, but none of the drugs for which we had less data were clearly better or worse.
Chronic insomnia is characterized by difficulty falling asleep or risk of psychological dependence and side effects including daytime chronic insomnia with 10 mg of the sleeping pill zolpidem (Ambien) for four weeks.
This supports the 2013 decision of the FDA which required lowering the recommended dose of the sleep medication zolpidem in non-elderly women, citing a risk of next-morning impairment, including problems with alertness while driving. The Penn study also offers the first data confirming that 5 mg can be effective as a maintenance strategy.
University of Pennsylvania Health System.
PHILADELPHIA – The roughly nine million Americans who rely on prescription sleeping pills to treat chronic insomnia may be able to get relief from as little as half of the drugs, and may even be helped by taking placebos in the treatment plan, according to new research published today in the journal Sleep Medicine by researchers from the Perelman School of Medicine at the University of Pennsylvania.